About GLPION

GLPION is a peptide API platform aggregating a vetted network of Chinese cGMP manufacturers, with 20+ peptide APIs and credentials disclosed per product.

Who We Are

A GLP-1-focused peptide API platform supplying licensed pharmaceutical companies in patent-expired markets and qualified research institutions worldwide, through a vetted network of Chinese cGMP manufacturers.

Vetted manufacturer network: GLPION aggregates Chinese cGMP peptide API manufacturers, screened for GMP, DMF validity, capacity and regulatory status.
Credentials per product: each product lists its supplier and documents — DMF (where held), GMP certificate and batch COA.
Product platform: 20+ peptide APIs across four lines — GLP-1 analogues, growth-hormone secretagogues, research peptides and biomedicinal enzymes.
NDC listed: platform labeler registration under FDA NDC codes 83589 & 83821.
Compliance-first strategy: supply aligned with each market's patent and regulatory status — commercial supply where patents have expired, research use (RUO) elsewhere.

Direct contact: info@glpionapi.com

GLPION pharmaceutical manufacturing facility

Platform at a Glance

DMF-Covered GLP-1 Line

Semaglutide, liraglutide, tirzepatide and retatrutide sourced from DMF-holding manufacturers (039209 / 033912 / 040378 / 042689).

20+ Peptide APIs

GLP-1 analogues, growth-hormone secretagogues, research peptides and biomedicinal enzymes.

NDC Listed

Platform labeler registration under FDA NDC codes 83589 & 83821.

Markets & Compliance

We align supply with patent and regulatory status in each market:

Brazil — semaglutide compound patent expired March 2026; supply to ANVISA-registered manufacturers for commercial production.
China — compound patent expired March 2026.
Australia — generic-entry window ~April 2027; partnership supply under discussion, research use now.
United States — compound patent restricts US use to research until December 2031; supply to the US is verified per supplier import status.